Oruka Therapeutics and Paragon Therapeutics executed a first amendment to their IL-23 license agreement dated May 29, 2026, expanding the Field definition from inflammatory bowel disease to all therapeutic areas. The amendment broadens Oruka's development rights and commercial opportunities for IL-23 targeted therapeutics across multiple indications.